Just as they did during the heparin crisis a decade ago, pharmaceutical companies must coordinate on coronavirus, Rx-360 CEO says.
The pharmaceutical industry needs to coordinate its preparations for likely supply chain threats from the 2019-nCoV coronavirus, perhaps by convening a summit, Rx-360 CEO Jim Fries told the Pink Sheet.
Rx-360, a not-for-profit industry consortium that formed a decade ago in response to the economically motivated adulteration of heparin active pharmaceutical ingredient in China, could serve as a conduit for such a summit, Fries added
As the US FDA expands unannounced foreign inspections building on pilots in India and China, experts expect higher scrutiny of overseas sites and perhaps even an industry shakeout in the longer term, though staffing and enforcement challenges could slow things down.
Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a federal 232 investigation.
Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.
